In some people who recovered from COVID-19, levels of antibodies targeting the thyroid increased over six months, which may indicate a change in immune activity toward the thyroid gland. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether anti-TPO elevation after COVID-19 is more common than after other viral infections or in the general population.
A systematic review and meta-analysis of all prospective studies measuring anti-TPO before and after confirmed SARS-CoV-2 infection, comparing changes in antibody titers to matched controls with influenza or no infection, including at least 10,000 participants.
An RCT could test whether blocking specific immune pathways during acute infection prevents anti-TPO elevation in high-risk individuals.
A double-blind RCT of 400 adults with pre-existing anti-TPO >50 IU/mL and confirmed COVID-19, randomized to receive intravenous IVIG vs. placebo during hospitalization, with primary outcome being change in anti-TPO titer at 6 months.
A prospective cohort could confirm the incidence and trajectory of anti-TPO elevation in COVID-19 survivors over time.
A multicenter prospective cohort of 1,200 adults with confirmed COVID-19, measuring anti-TPO at admission, discharge, 3 months, and 6 months, with baseline levels available, adjusting for age, sex, and pre-existing autoimmune conditions.
A case-control study could compare anti-TPO levels in post-COVID patients with and without thyroid dysfunction to identify immune markers predictive of progression.
A matched case-control study of 250 post-COVID patients with elevated anti-TPO (>100 IU/mL) and 250 without, matched for age, sex, and acute illness severity, measuring anti-Tg, TSH, and cytokine profiles at 6 months.
A cross-sectional study could estimate the prevalence of elevated anti-TPO in a single group of recovered patients.
A single-timepoint survey of 600 adults 6 months after hospital discharge for COVID-19, measuring anti-TPO to estimate prevalence and crude association with acute illness severity.